Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug OMS721 tested for rare kidney conditions

NCT ID NCT02682407

Terminated Disease control Sponsor: Omeros Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3G are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy dense deposit disease IgA glomerulonephritis IgA nephropathy, susceptibility to, 1 lobular neoplasia lupus nephritis membranous glomerulonephritis nemaline myopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3G IGAN LN MN

Contacts and locations

Locations

  • Omeros Investigational Site

    Denver, Colorado, 80230, United States

  • Omeros Investigational Site

    Augusta, Georgia, 30909, United States

  • Omeros Investigational Site

    Lawrenceville, Georgia, 30046, United States

  • Omeros Investigational Site

    Evergreen Park, Illinois, 60805, United States

  • Omeros Investigational Site

    Voorhees Township, New Jersey, 08043, United States

  • Omeros Investigational Site

    Flushing, New York, 11355, United States

  • Omeros Investigational Site

    San Antonio, Texas, 78215, United States

  • Omeros Investigational Site

    Milwaukee, Wisconsin, 53226, United States

  • Omeros Investigational Site

    Chai Wan, Hong Kong

  • Omeros Investigational Site

    Hong Kong, Hong Kong

  • Omeros Investigational Site

    Kowloon, Hong Kong

  • Omeros Investigational Site

    Shatin, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.